These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21747004)

  • 1. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
    Wolk DA; Grachev ID; Buckley C; Kazi H; Grady MS; Trojanowski JQ; Hamilton RH; Sherwin P; McLain R; Arnold SE
    Arch Neurol; 2011 Nov; 68(11):1398-403. PubMed ID: 21747004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.
    Wong DF; Moghekar AR; Rigamonti D; Brašić JR; Rousset O; Willis W; Buckley C; Smith A; Gok B; Sherwin P; Grachev ID
    Mol Imaging Biol; 2013 Apr; 15(2):230-7. PubMed ID: 22878921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.
    Leinonen V; Rinne JO; Virtanen KA; Eskola O; Rummukainen J; Huttunen J; von Und Zu Fraunberg M; Nerg O; Koivisto AM; Rinne J; Jääskeläinen JE; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajärvi M; Heurling K; Grachev ID
    Eur J Neurol; 2013 Jul; 20(7):1043-52. PubMed ID: 23398333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus.
    Rinne JO; Frantzen J; Leinonen V; Lonnrot K; Laakso A; Virtanen KA; Solin O; Kotkansalo A; Koivisto A; Sajanti J; Karppinen A; Lehto H; Rummukainen J; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajarvi M; Grachev ID
    Neurodegener Dis; 2014; 13(4):237-45. PubMed ID: 24296542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.
    Leinonen V; Rinne JO; Wong DF; Wolk DA; Trojanowski JQ; Sherwin PF; Smith A; Heurling K; Su M; Grachev ID
    Acta Neuropathol Commun; 2014 Apr; 2():46. PubMed ID: 24755237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
    Curtis C; Gamez JE; Singh U; Sadowsky CH; Villena T; Sabbagh MN; Beach TG; Duara R; Fleisher AS; Frey KA; Walker Z; Hunjan A; Holmes C; Escovar YM; Vera CX; Agronin ME; Ross J; Bozoki A; Akinola M; Shi J; Vandenberghe R; Ikonomovic MD; Sherwin PF; Grachev ID; Farrar G; Smith AP; Buckley CJ; McLain R; Salloway S
    JAMA Neurol; 2015 Mar; 72(3):287-94. PubMed ID: 25622185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of amyloid distribution by [
    Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
    Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal and anatomical distribution of
    Yun T; Lee W; Kang JH; Yang MP; Kang BT
    BMC Vet Res; 2020 Jan; 16(1):17. PubMed ID: 31952531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.
    Beach TG; Thal DR; Zanette M; Smith A; Buckley C
    J Alzheimers Dis; 2016 Mar; 52(3):863-73. PubMed ID: 27031469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
    Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
    Vandenberghe R; Nelissen N; Salmon E; Ivanoiu A; Hasselbalch S; Andersen A; Korner A; Minthon L; Brooks DJ; Van Laere K; Dupont P
    Neuroimage; 2013 Jan; 64():517-25. PubMed ID: 22982358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance in detecting amyloid positivity between
    Cho SH; Choe YS; Kim YJ; Lee B; Kim HJ; Jang H; Kim JP; Jung YH; Kim SJ; Kim BC; Farrar G; Na DL; Moon SH; Seo SW
    Sci Rep; 2020 Nov; 10(1):19576. PubMed ID: 33177593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.